Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Revolution Medicines, Inc.RVMD · Entity 606 | Director · See Remarks | September 16, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Revolution Medicines, Inc.
Report date September 16, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 267,117 |
Reported balance
After 2026-09-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-16 · Sale · Disposed 213 · Balance 267,117 F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. F2: The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 253,342 |
Reported balance
After 2026-09-16 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-16 · Sale · Disposed 13,775 · Balance 253,342 F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. F3: Includes 157,588 restricted stock units. |
| Common StockSEC Table I · non-derivative | IndirectTrust | 594,060 |
Reported balance
Holding disclosure · report date 2026-09-16 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 594,060 F4: Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust. |
| Common StockSEC Table I · non-derivative | IndirectTrust | 61,424 |
Reported balance
Holding disclosure · report date 2026-09-16 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 61,424 F5: Held by Jonathan Goldsmith Revocable Trust. |
| Common StockSEC Table I · non-derivative | IndirectTrust | 61,424 |
Reported balance
Holding disclosure · report date 2026-09-16 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 61,424 F6: Held by Rebecca Goldsmith Revocable Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.
F2: The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3: Includes 157,588 restricted stock units.
F4: Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.
F5: Held by Jonathan Goldsmith Revocable Trust.
F6: Held by Rebecca Goldsmith Revocable Trust.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CONSTELLATION PHARMACEUTICALS INC
Report date July 15, 2021 · Filed July 19, 2021
Section 16 reporting ended · disclosed 2021-07-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 1
1 source rowRow 1 · 2021-07-15 · Disposition to issuer · Disposed 89,857 · Balance 0 F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the "Agreement"), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.57 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-07-15 · Disposition to issuer · Disposed 13,171 · Balance 0 F2: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.50 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-07-15 · Disposition to issuer · Disposed 6,825 · Balance 0 F2: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.12 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-07-15 · Disposition to issuer · Disposed 13,171 · Balance 0 F2: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.60 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-07-15 · Disposition to issuer · Disposed 12,446 · Balance 0 F2: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.51 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-07-15 · Disposition to issuer · Disposed 9,083 · Balance 0 F2: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.52 | Direct | 0 |
Reported balance
After 2021-07-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-07-15 · Disposition to issuer · Disposed 13,171 · Balance 0 F2: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration"). |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the "Agreement"), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
F2: This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the "Company"), MorphoSys AG ("Parent") and MorphoSys Development Inc. ("Purchaser"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the "Effective Time"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the "Merger"). In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the "Merger Consideration").
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2020 Filed Aug 14, 2020 22:32 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 100 | $27.51 | $2,751.00 |
DisclosureSEC source: 0001567619-20-015580 · doc1.xml · nonDerivative · entry 9 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Disclosed balance after: 137,752 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F10 · ownership.nature: Held by the Goldsmith Children 2011 Irrevocable Education Trust. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 22:32 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 600 | $26.76 | $16,054.02 |
DisclosureSEC source: 0001567619-20-015580 · doc1.xml · nonDerivative · entry 8 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Disclosed balance after: 137,852 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F6 · price: The transaction was executed in multiple trades in prices ranging from $26.36 to $27.08, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F10 · ownership.nature: Held by the Goldsmith Children 2011 Irrevocable Education Trust. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 22:32 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 5,400 | $25.79 | $139,248.72 |
DisclosureSEC source: 0001567619-20-015580 · doc1.xml · nonDerivative · entry 7 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Disclosed balance after: 138,452 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F5 · price: The transaction was executed in multiple trades in prices ranging from $25.36 to $26.33, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F10 · ownership.nature: Held by the Goldsmith Children 2011 Irrevocable Education Trust. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 22:32 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 400 | $27.73 | $11,090.00 |
DisclosureSEC source: 0001567619-20-015580 · doc1.xml · nonDerivative · entry 6 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The transaction was executed in multiple trades in prices ranging from $27.29 to $28.00, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 22:32 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 400 | $1.12 | $448.00 |
DisclosureSEC source: 0001567619-20-015580 · doc1.xml · nonDerivative · entry 5 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 22:32 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,983 | $26.63 | $52,810.86 |
DisclosureSEC source: 0001567619-20-015580 · doc1.xml · nonDerivative · entry 4 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $26.25 to $27.08, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 22:32 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 1,983 | $1.12 | $2,220.96 |
DisclosureSEC source: 0001567619-20-015580 · doc1.xml · nonDerivative · entry 3 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,983 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 22:32 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 14,584 | $25.77 | $375,858.85 |
DisclosureSEC source: 0001567619-20-015580 · doc1.xml · nonDerivative · entry 2 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $25.25 to $26.20, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 22:32 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 14,584 | $1.12 | $16,334.08 |
DisclosureSEC source: 0001567619-20-015580 · doc1.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 18:14 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | GrantStock Options (Right to buy) · Derivative | 13,171 | $0.00 Strike: $37.52 | $0.00 |
DisclosureSEC source: 0001562180-20-004332 · primarydocument.xml · derivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,171 Underlying: Common Stock · 13,171 shares Expires 2030-06-04 F1 · derivative.exercise_date: This option was granted on June 4, 2020, and the shares underlying the option vest in equal quarterly installments through June 4, 2021, subject to continued service. Read SEC document |
| May 12, 2020 Filed May 13, 2020 18:29 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (right to buy) · Derivative | 1,300 | $0.00 Strike: $7.60 | $0.00 |
DisclosureSEC source: 0001562180-20-003588 · primarydocument.xml · derivative · entry 10 GOLDSMITH MARK A · CIK 0001246842 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,446 Underlying: Common Stock · 1,300 shares Expires 2028-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on March 8, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through March 8, 2021. Read SEC document |
| May 12, 2020 Filed May 13, 2020 18:29 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (right to buy) · Derivative | 300 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001562180-20-003588 · primarydocument.xml · derivative · entry 9 GOLDSMITH MARK A · CIK 0001246842 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,825 Underlying: Common Stock · 300 shares Expires 2028-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on July 19, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through July 19, 2021. Read SEC document |
| May 12, 2020 Filed May 13, 2020 18:29 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (right to buy) · Derivative | 2,625 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001562180-20-003588 · primarydocument.xml · derivative · entry 8 GOLDSMITH MARK A · CIK 0001246842 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,987 Underlying: Common Stock · 2,625 shares Expires 2021-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Shares are fully vested. Read SEC document |
| May 12, 2020 Filed May 13, 2020 18:29 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 4,225 | $50.05 | $211,474.35 |
DisclosureSEC source: 0001562180-20-003588 · primarydocument.xml · nonDerivative · entry 6 GOLDSMITH MARK A · CIK 0001246842 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by Trusts for which Mark A. Goldsmith is a Trustee Disclosed balance after: 143,063 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $50.00 to $50.49. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 12, 2020 Filed May 13, 2020 18:29 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 1,300 | $7.60 | $9,880.00 |
DisclosureSEC source: 0001562180-20-003588 · primarydocument.xml · nonDerivative · entry 5 GOLDSMITH MARK A · CIK 0001246842 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by Trusts for which Mark A. Goldsmith is a Trustee Disclosed balance after: 147,288 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2020 Filed May 13, 2020 18:29 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 300 | $11.50 | $3,450.00 |
DisclosureSEC source: 0001562180-20-003588 · primarydocument.xml · nonDerivative · entry 4 GOLDSMITH MARK A · CIK 0001246842 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by Trusts for which Mark A. Goldsmith is a Trustee Disclosed balance after: 145,988 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2020 Filed May 13, 2020 18:29 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 2,625 | $1.55 | $4,068.75 |
DisclosureSEC source: 0001562180-20-003588 · primarydocument.xml · nonDerivative · entry 3 GOLDSMITH MARK A · CIK 0001246842 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by Trusts for which Mark A. Goldsmith is a Trustee Disclosed balance after: 145,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2020 Filed May 13, 2020 18:29 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (right to buy) · Derivative | 100 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001562180-20-003588 · primarydocument.xml · derivative · entry 7 GOLDSMITH MARK A · CIK 0001246842 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,612 Underlying: Common Stock · 100 shares Expires 2021-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Shares are fully vested. Read SEC document |
| May 11, 2020 Filed May 13, 2020 18:29 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 100 | $50.00 | $5,000.00 |
DisclosureSEC source: 0001562180-20-003588 · primarydocument.xml · nonDerivative · entry 2 GOLDSMITH MARK A · CIK 0001246842 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by Trusts for which Mark A. Goldsmith is a Trustee Disclosed balance after: 143,063 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 11, 2020 Filed May 13, 2020 18:29 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 100 | $1.55 | $155.00 |
DisclosureSEC source: 0001562180-20-003588 · primarydocument.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by Trusts for which Mark A. Goldsmith is a Trustee Disclosed balance after: 143,163 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2020 Filed May 7, 2020 16:25 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (right to buy) · Derivative | 3,900 | $0.00 Strike: $7.60 | $0.00 |
DisclosureSEC source: 0001562180-20-003451 · primarydocument.xml · derivative · entry 14 GOLDSMITH MARK A · CIK 0001246842 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,746 Underlying: Common Stock · 3,900 shares Expires 2028-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option was granted on March 8, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through March 8, 2021. Read SEC document |
| May 06, 2020 Filed May 7, 2020 16:25 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (right to buy) · Derivative | 750 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001562180-20-003451 · primarydocument.xml · derivative · entry 13 GOLDSMITH MARK A · CIK 0001246842 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,125 Underlying: Common Stock · 750 shares Expires 2028-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on July 19, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through July 19, 2021. Read SEC document |
| May 06, 2020 Filed May 7, 2020 16:25 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (right to buy) · Derivative | 6,813 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001562180-20-003451 · primarydocument.xml · derivative · entry 12 GOLDSMITH MARK A · CIK 0001246842 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,712 Underlying: Common Stock · 6,813 shares Expires 2021-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Shares are fully vested. Read SEC document |
| May 06, 2020 Filed May 7, 2020 16:25 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 11,463 | $45.06 | $516,544.56 |
DisclosureSEC source: 0001562180-20-003451 · primarydocument.xml · nonDerivative · entry 8 GOLDSMITH MARK A · CIK 0001246842 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by Trusts for which Mark A. Goldsmith is a Trustee Disclosed balance after: 143,063 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $45.00 to $45.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 06, 2020 Filed May 7, 2020 16:25 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 3,900 | $7.60 | $29,640.00 |
DisclosureSEC source: 0001562180-20-003451 · primarydocument.xml · nonDerivative · entry 7 GOLDSMITH MARK A · CIK 0001246842 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by Trusts for which Mark A. Goldsmith is a Trustee Disclosed balance after: 154,526 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2020 Filed May 7, 2020 16:25 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 750 | $11.50 | $8,625.00 |
DisclosureSEC source: 0001562180-20-003451 · primarydocument.xml · nonDerivative · entry 6 GOLDSMITH MARK A · CIK 0001246842 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by Trusts for which Mark A. Goldsmith is a Trustee Disclosed balance after: 150,626 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2020 Filed May 7, 2020 16:25 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 6,813 | $1.55 | $10,560.15 |
DisclosureSEC source: 0001562180-20-003451 · primarydocument.xml · nonDerivative · entry 5 GOLDSMITH MARK A · CIK 0001246842 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by Trusts for which Mark A. Goldsmith is a Trustee Disclosed balance after: 149,876 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2020 Filed May 7, 2020 16:25 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (right to buy) · Derivative | 520 | $0.00 Strike: $7.60 | $0.00 |
DisclosureSEC source: 0001562180-20-003451 · primarydocument.xml · derivative · entry 11 GOLDSMITH MARK A · CIK 0001246842 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,646 Underlying: Common Stock · 520 shares Expires 2028-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option was granted on March 8, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through March 8, 2021. Read SEC document |
| May 05, 2020 Filed May 7, 2020 16:25 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (right to buy) · Derivative | 300 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001562180-20-003451 · primarydocument.xml · derivative · entry 10 GOLDSMITH MARK A · CIK 0001246842 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,875 Underlying: Common Stock · 300 shares Expires 2028-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on July 19, 2018. The shares underlying the option are scheduled to vest in equal quarterly installments through July 19, 2021. Read SEC document |
| May 05, 2020 Filed May 7, 2020 16:25 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (right to buy) · Derivative | 2,325 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001562180-20-003451 · primarydocument.xml · derivative · entry 9 GOLDSMITH MARK A · CIK 0001246842 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,525 Underlying: Common Stock · 2,325 shares Expires 2021-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Shares are fully vested. Read SEC document |
| May 05, 2020 Filed May 7, 2020 16:25 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 3,145 | $40.01 | $125,823.90 |
DisclosureSEC source: 0001562180-20-003451 · primarydocument.xml · nonDerivative · entry 4 GOLDSMITH MARK A · CIK 0001246842 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by Trusts for which Mark A. Goldsmith is a Trustee Disclosed balance after: 143,063 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $40.00 to $40.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 05, 2020 Filed May 7, 2020 16:25 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 520 | $7.60 | $3,952.00 |
DisclosureSEC source: 0001562180-20-003451 · primarydocument.xml · nonDerivative · entry 3 GOLDSMITH MARK A · CIK 0001246842 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by Trusts for which Mark A. Goldsmith is a Trustee Disclosed balance after: 146,208 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2020 Filed May 7, 2020 16:25 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 300 | $11.50 | $3,450.00 |
DisclosureSEC source: 0001562180-20-003451 · primarydocument.xml · nonDerivative · entry 2 GOLDSMITH MARK A · CIK 0001246842 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by Trusts for which Mark A. Goldsmith is a Trustee Disclosed balance after: 145,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2020 Filed May 7, 2020 16:25 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 2,325 | $1.55 | $3,603.75 |
DisclosureSEC source: 0001562180-20-003451 · primarydocument.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by Trusts for which Mark A. Goldsmith is a Trustee Disclosed balance after: 145,388 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 27, 2020 Filed Apr 29, 2020 20:20 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionStock Option (Right to Buy) · Derivative | 400 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001562180-20-003210 · primarydocument.xml · derivative · entry 3 GOLDSMITH MARK A · CIK 0001246842 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,850 Underlying: Common Stock · 400 shares Expires 2021-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Shares are fully vested. Read SEC document |
| April 27, 2020 Filed Apr 29, 2020 20:20 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | SaleCommon Stock | 400 | $40.12 | $16,049.00 |
DisclosureSEC source: 0001562180-20-003210 · primarydocument.xml · nonDerivative · entry 2 GOLDSMITH MARK A · CIK 0001246842 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by Trusts for which Mark A. Goldsmith is a Trustee Disclosed balance after: 143,063 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $40.03 to $40.16. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 27, 2020 Filed Apr 29, 2020 20:20 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | Exercise / conversionCommon Stock | 400 | $1.55 | $620.00 |
DisclosureSEC source: 0001562180-20-003210 · primarydocument.xml · nonDerivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by Trusts for which Mark A. Goldsmith is a Trustee Disclosed balance after: 143,463 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:23 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 128,439 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001567619-20-004019 · doc1.xml · derivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,439 Underlying: Common Stock · 128,439 shares Expires 2030-02-11 F1 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest with respect to 1/48 of the shares subject thereto on each monthly anniversary of February 12, 2020, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 16:49 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | GrantStock Option (right to buy) · Derivative | 13,171 | $0.00 Strike: $9.12 | $0.00 |
DisclosureSEC source: 0000899243-19-016205 · doc4.xml · derivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,171 Underlying: Common Stock · 13,171 shares Expires 2029-06-05 F1 · derivative.exercise_date: This option was granted on June 6, 2019 and will vest as to all shares underlying the option on June 6, 2020, subject to continued service. Read SEC document |
| July 19, 2018 Filed Jul 20, 2018 17:42 UTC | CONSTELLATION PHARMACEUTICALS INC CNST · Entity 137050 | GrantStock Option (right to buy) · Derivative | 8,175 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0000899243-18-020285 · doc4.xml · derivative · entry 1 GOLDSMITH MARK A · CIK 0001246842 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,175 Underlying: Common Stock · 8,175 shares Expires 2028-07-18 F1 · derivative.exercise_date: This option was granted on July 19, 2018 and is scheduled to vest in equal monthly installments through July 19, 2021, subject to continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.